IPO - InflaRx N.V.

Form Type: 424B5

Filing Date: 2025-02-13

Corporate Action: Ipo

Type: New

Accession Number: 000114036125004369

Filing Summary: InflaRx N.V. is launching an offer and sale of ordinary shares and pre-funded warrants through a preliminary prospectus supplement. The offering includes ordinary shares priced at €0.12 each and pre-funded warrants to purchase ordinary shares at an exercise price of 0.001, reflecting the public offering price of the shares. As of February 12, 2025, ordinary shares were last priced at $2.57 on Nasdaq. The underwriters have a 30-day option to purchase additional ordinary shares at the public price. InflaRx's business focuses on anti-inflammatory therapeutics targeting the complement system, with notable products such as vilobelimab for COVID-19 treatment, which received Emergency Use Authorization in the U.S. and Market Authorization in the EU. The company aims to advance its lead product while expanding its portfolio of therapies for C5a receptor antagonists, including INF904 and IFX002. Recent achievements include positive CHMP recommendations for vilobelimab's use and the initiation of a Phase 2a study for its oral C5aR inhibitor. This offering supports their commercialization efforts and ongoing clinical trials.

Document Link: View Document